Travere Therapeutics has achieved two significant FDA approvals for FILSPARI, driving notable revenue growth. See why I rate ...
A novel molecule plus rituximab was associated with higher response rates vs. rituximab alone, according to study data ...
Q3 earnings swing to loss as revenue rises Travere Therapeutics (TVTX) just delivered third quarter 2026 numbers that pulled investor attention to both sides of the income statement. Revenue reached ...
Shares of Travere Therapeutics took a hit Tuesday, but closed in the green, after fewer than expected patients started taking its drug.
UBS Global Biopharma Conference 2026 November 16, 2026 6:20 AM EST Hello. All right. Thank you, everyone, for coming today. My name is Dejia Zhang, and I'm on the UBS Investment Banking coverage team.
Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI® (sparsentan) may modify the underlying disease ...
Revenue went the other way. It reached $224.56 million, beating the $192.52 million consensus by 16.6% and growing 36.2% year over year. FILSPARI net sales crossed $200 million for the first time, ...
Travere Therapeutics has delivered a very large 3 year share price gain, which naturally puts the spotlight on whether the current valuation can be explained by its sales base. With the stock around ...
Travere Therapeutics (NasdaqGM: TVTX) reported new biomarker data from the Phase 3 PROTECT Study of FILSPARI in IgA ...
Everest Medicines raised HK$1.57B via a 2025 share placement, but its stock fell 63% by 2026 despite 142% revenue growth and ...